Title: Impact of Pathological Complete Response on Survival in Gastric Cancer After
Neoadjuvant Chemotherapy: A Propensity Score Matching Analysis
Version: 0 Date: 15 Jul 2024
Reviewer's report:
Paper title: Neoadjuvant Chemotherapy Primarily Benefits Locally Advanced Gastric Cancer
Patients with Pathological Complete Response
Authors: Dr. Yonghe Chen, Dr. Lei Lian, Dr. Junsheng Peng
This is a potentially interesting report which clarified NAC primarily offers survival benefits for
LAGC patients who achieve pCR.  It's a very ordered method and analysis.
However, there are some important issues to be discussed more in order to make this paper more
valuable.  The authors should consider the following questions and answer them adequately.
While the authors mentioned the reason why gastric cancer is less likely to benefit of NAC,
previous studies such as `RESOLVE` have shown that there is a treatment advantage with NAC.
However, in this study, the NAC group had no advantage over the AC group even after
propensity score matching? In other words, this study is aimed at patients who are less likely
to benefit of NAC.
What makes this study different from previous studies? We need to understand precisely as this
is the most important point that prompted this research.
`pCR` is a factor according to the result of treatment. Unfortunately, it is not possible to select
the pCR group before NAC. Were there any pretreatment factors related to tumor regression?
I would like to request additional analysis.
Title: Impact of Pathological Complete Response on Survival in Gastric Cancer After
Neoadjuvant Chemotherapy: A Propensity Score Matching Analysis
Version: 0 Date: 15 Jul 2024
Reviewer's report:
Paper title: Neoadjuvant Chemotherapy Primarily Benefits Locally Advanced Gastric Cancer
Patients with Pathological Complete Response
Authors: Dr. Yonghe Chen, Dr. Lei Lian, Dr. Junsheng Peng
This is a potentially interesting report which clarified NAC primarily offers survival benefits for
LAGC patients who achieve pCR.  It's a very ordered method and analysis.
However, there are some important issues to be discussed more in order to make this paper more
valuable.  The authors should consider the following questions and answer them adequately.
While the authors mentioned the reason why gastric cancer is less likely to benefit of NAC,
previous studies such as `RESOLVE` have shown that there is a treatment advantage with NAC.
However, in this study, the NAC group had no advantage over the AC group even after
propensity score matching? In other words, this study is aimed at patients who are less likely
to benefit of NAC.
What makes this study different from previous studies? We need to understand precisely as this
is the most important point that prompted this research.
`pCR` is a factor according to the result of treatment. Unfortunately, it is not possible to select
the pCR group before NAC. Were there any pretreatment factors related to tumor regression?
I would like to request additional analysis.
Please review this paper.
user
Title: Impact of Pathological Complete Response on Survival in Gastric Cancer After
Neoadjuvant Chemotherapy: A Propensity Score Matching Analysis
Version: 0 Date: 15 Jul 2024
Reviewer's report:
Paper title: Neoadjuvant Chemotherapy Primarily Benefits Locally Advanced Gastric Cancer
Patients with Pathological Complete Response
Authors: Dr. Yonghe Chen, Dr. Lei Lian, Dr. Junsheng Peng
This is a potentially interesting report which clarified NAC primarily offers survival benefits for
LAGC patients who achieve pCR.  It's a very ordered method and analysis.
However, there are some important issues to be discussed more in order to make this paper more
valuable.  The authors should consider the following questions and answer them adequately.
While the authors mentioned the reason why gastric cancer is less likely to benefit of NAC,
previous studies such as `RESOLVE` have shown that there is a treatment advantage with NAC.
However, in this study, the NAC group had no advantage over the AC group even after
propensity score matching? In other words, this study is aimed at patients who are less likely
to benefit of NAC.
What makes this study different from previous studies? We need to understand precisely as this
is the most important point that prompted this research.
`pCR` is a factor according to the result of treatment. Unfortunately, it is not possible to select
the pCR group before NAC. Were there any pretreatment factors related to tumor regression?
I would like to request additional analysis.
assistant